Patent intelligence · US
US 9663790
Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
Patent details — US 9663790
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 30, 2017
- Expiration
- May 25, 2037
- Applicant
- The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
- Claims
- 17
- CPC classes
- A61K, A61K48/0058, A61K48/0066, A61P
Quick answer
US 9663790 (Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression) is held by The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center. Status: granted. Granted May 30, 2017. Expires May 25, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K48/0058, A61K48/0066, A61P, A61P3/04
More from The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
Related pharmaceutical patents in our USPTO index.
-
US 12279630
Treatment and prevention of seed allergies
granted -
US 12251417
Antimicrobial compounds from the genus Delftia
granted -
US 12139522
T-cells comprising two different chimeric antigen receptors and uses thereof
granted -
US 12134650
Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer
granted -
US 12084350
Allotrope of carbon having increased electron delocalization
granted -
US 12023348
EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
granted -
US 11944644
T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof
granted -
US 11932871
Methods of culturing t cells and uses of same
granted
Frequently asked questions
What is US patent 9663790?
US 9663790 (Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression) is held by The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center. Status: granted. Granted May 30, 2017. Expires May 25, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9663790?
The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 93 pharmaceutical patents for this assignee.
When does US 9663790 expire?
Our index shows an expiration date of May 25, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.